Geert Kersten, the CEO of drugmaker Cel-Sci, stopped communicating publicly soon after the company’s cancer drug failed to prolong the survival of patients in a large clinical trial last June. Privately, Kersten is talking to select investors. And what he’s telling them could land him and Cel-Sci in trouble with federal regulators.
During a conference call last Wednesday, Kersten tipped off an invitation-only group of investors and brokers about Cel-Sci’s plan to issue a “major press release” later this week, possibly on Thursday, related to its cancer drug, called Multikine. The press release was to be issued simultaneously with a posting of Multikine clinical trial data on the government’s ClinicalTrials.gov website, Kersten said.
A participant provided STAT with access to the call and I heard Kersten’s entire presentation live. He also answered questions from listeners. The call was organized by an investor relations firm and lasted about 30 minutes.
Exciting news! STAT has moved its comment section to our subscriber-only app, STAT+ Connect. Subscribe to STAT+ today to join the conversation or join us on Twitter, Facebook, LinkedIn, and Threads. Let's stay connected!
To submit a correction request, please visit our Contact Us page.